Metastatic Castrate Resistant Prostate Cancer (mCRPC) Clinical Trials

36 clinical trials for Metastatic Castrate Resistant Prostate Cancer (mCRPC) across international registries, including 5 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Investigating SX-682 in Combination With Apalutamide in Metastatic Castration-resistant Prostate Cancer — RECRUITING · PHASE1
• Personalized vs. Fixed-Activity 177Lu-PSMA-617 Radiopharmaceutical Therapy (PRODIGY-2) — RECRUITING · PHASE1
• Carboplatin or Olaparib for BRcA Deficient Prostate Cancer — RECRUITING · PHASE2
• Study of XNW5004 Tablet in Combination With Enzalutamide in Subjects With Metastatic Castration-Resistant Prostate Cancer — RECRUITING · PHASE1
• Kidney Function and Risk Factors in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Undergoing 177Lutetium-PSMA Radioligand Therapy: a Prospective Observational Study - KiRi-Trial — RECRUITING
• Randomized, open-label, parallel-group, multi-centre phase II clinical trial with active cellular immunotherapy DCVAC/PCa in patients with castrate-resistant prostate cancer — COMPLETED · PHASE2
• Sipuleucel-T Manufacturing Demonstration Study — COMPLETED · PHASE2
• Double-blind Study of Denosumab Compared With Zoledronic Acid in the Treatment of Bone Metastases in Men With Hormone-refractory Prostate Cancer — COMPLETED · PHASE3
• A Phase 1b/2 Study of Docetaxel and Prednisone, with or without ISIS 183750 (an eIF4E Inhibitor), inPatients with Castrate-Resistant Prostate Cancer — COMPLETED · PHASE2
• Nivolumab and ipilimumab treatment in prostate cancer with an immunogenic signature — OTHER · PHASE2
• LuX: Xaluritamig in Participants With Metastatic Castrate Resistant Prostate Cancer and Suboptimal Response to Lutetium 177 Vipivotide Tetraxetan — NOT_YET_RECRUITING · PHASE2
• A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1). — ACTIVE_NOT_RECRUITING · PHASE3
• TmPSMA-02 in mCRPC — ACTIVE_NOT_RECRUITING · PHASE1
• (20510) A Phase 4, randomized, open-label, multicenter efficacy and safety study of standard dose of radium-223 dichloride vs. standard doses of androgen receptor pathway inhibitor (ARPI) in patients with bone dominant metastatic castration resistant prostate cancer (mCRPC) progressing on/after one line of ARPI — TERMINATED · PHASE4
• RADIANT: A Study of Radium-223 Dichloride (Xofigo) vs Enzalutamide or Abiraterone (ARPIs, Androgen Receptor Pathway Inhibitors) in Patients With Prostate Cancer That Has Spread to the Bones (mCRPC, Metastatic Castration-Resistant Prostate Cancer) — ACTIVE_NOT_RECRUITING · PHASE4
• A Study of Mevrometostat With Enzalutamide in People With Prostate Cancer Who Have Previously Received Androgen Receptor Pathway Inhibitor Therapy — NOT_YET_RECRUITING · PHASE2
• Study of Alpha Radioligand Therapy AB001 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) — ACTIVE_NOT_RECRUITING · PHASE1
• TulmiSTAR-01: A two-part, Phase I dose escalation and expansion followed by a randomized, open-label multicenter, Phase II study to assess the safety and efficacy of the combination of tulmimetostat (DZR123) and JSB462 (luxdegalutamide) vs standard of care in patients with progressive metastatic castrate resistant prostate cancer — TERMINATED · PHASE2
• A Phase 1, Open-Label, Study Evaluating the Safety, Pharmacokinetics, and Clinical Effects of Intravenously Administered PT-112 Injection in Patients with Advanced Solid Tumors and Subsequent Expansion Cohorts — TERMINATED · PHASE2
• Fractionated Docetaxel and Radium 223 in Metastatic Castration-Resistant Prostate Cancer — COMPLETED · PHASE1
• MGC018 With or Without MGA012 in Advanced Solid Tumors — TERMINATED · PHASE1
• Phase Ib Trial of 177Lu-PSMA-I&T Therapy in Combination With Olaparib and Pembrolizumab in Patients With Metastatic Castration Resistant Prostate Cancer — NOT_YET_RECRUITING · PHASE1
• A Study Evaluating the Safety, Pharmacokinetics, and Clinical Effects of Intravenously Administered PT-112 Injection in Subjects With Advanced Solid Tumors and Subsequent Dose Expansion Cohorts — OTHER · PHASE2
• The Safety and Tolerability of GT0918 in Subjects With mHSPC and mCRPC — COMPLETED · PHASE2
• Masitinib Plus Docetaxel in Metastatic Castration-resistant Prostate Cancer — COMPLETED · PHASE3
• Detection of ARv7 in the Plasma of Men With Advanced Metastatic Castrate Resistant Prostate Cancer (MCRP) — SUSPENDED
• OGX-427 in Metastatic Castrate-Resistant Prostate Cancer With Prostate-Specific Antigen Progression While Receiving Abiraterone — TERMINATED · PHASE2
• Idronoxil Suppository Combine With Radiotherapy for Metastatic Prostate Cancer — TERMINATED · PHASE1
• Sipuleucel-T and Stereotactic Ablative Body Radiation (SABR) for Metastatic Castrate-resistant Prostate Cancer (mCRPC) — COMPLETED · PHASE2
• Phase 1/2A Study of TRC253, an Androgen Receptor Antagonist, in Metastatic Castration-resistant Prostate Cancer Patients — COMPLETED · PHASE1
• Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5829 (Alobresib) as a Single Agent and In Combination With Enzalutamide in Participants With Metastatic Castrate-Resistant Prostate Cancer — TERMINATED · PHASE1
• Observational Longitudinal Study of Pain in Men With Metastatic Castrate-Resistant Prostate Cancer — COMPLETED
• Safety, Tolerability, and PK of GT0918 (Proxalutamide) in Subjects With Metastatic Castrate Prostate Cancer — COMPLETED · PHASE1
• A Proof of Concept Study of Maintenance Therapy With Tasquinimod in Patients With Metastatic Castrate-resistant Prostate Cancer Who Are Not Progressing After a First Line Docetaxel Based Chemotherapy — TERMINATED · PHASE2
• Pharmacodynamic Study With FLT-PET/CT in Patients With Prostate/Other Solid Malignancies Treated With High Dose Axitinib — COMPLETED · PHASE1
• A Phase I/II Study of TRC105 in Metastatic Castrate Resistant Prostate Cancer (CRPC) — COMPLETED · PHASE1

Refine this search